Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT

Inclusion Criteria: * Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT * Age \>18 years * Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR. Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion). * Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up * Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen. * First IGEV course started before December 31st 2007 * Assessment of tumor response by Cheson 1999 criteria 11 Exclusion Criteria: * NONE